Flatiron Health, Inc.

Flatiron Health, Inc. is a New York-based healthcare technology company focused on improving cancer care through innovative software solutions and data integration for clinical research and treatment. Founded in 2012 and headquartered in New York, US, Flatiron Health, Inc. provides technology solutions for oncology practices.

The company was co-founded by Hugh Levaux, who has a history of entrepreneurial ventures. In 2018, Flatiron Health was acquired by Roche for USD 1. 9 billion, marking a significant pivot in its corporate structure. The company has been involved in 4 deals, with the most recent concluded in February 2018.

Flatiron Health specializes in technology solutions that enhance cancer care through its core products, primarily including Flatiron Clinical Pipe™ and Flatiron Assist™. Flatiron Clinical Pipe™ integrates electronic health records (EHR) with electronic data capture (EDC) systems, facilitating the seamless transfer of clinical trial data across 85 sites to enhance trial efficiency. Flatiron Assist™ is a clinical decision support tool designed to optimize treatment regimens by aligning with National Comprehensive Cancer Network (NCCN) guidelines, resulting in a significant reduction of 44% in the variety of treatment regimens ordered across participating cancer centers. These solutions are utilized by clinicians, researchers, and healthcare organizations across the United States, with a focus on improving patient experiences and operational efficiencies in oncology.

Additionally, Flatiron's evidence-based offerings support real-world data generation for regulatory agencies and healthcare providers, making its products invaluable across various markets within the healthcare sector. Flatiron Health's revenue model is primarily based on subscription services, partnerships, and direct sales to healthcare providers and institutions. The company engages in B2B transactions, providing its flagship products, such as Flatiron Clinical Pipe™ and Flatiron Assist™, to cancer treatment centers and research institutions. Revenue is generated through contractual agreements that may include ongoing support and updates for its software solutions, as well as tailored services that facilitate clinical research and improve patient care.

Specific pricing structures for these services are determined based on the unique needs of each client, often reflecting the level of integration and support required. Through these structured transactions, Flatiron Health effectively combines technology with clinical practice to drive advancements in oncology care and research. Flatiron Health plans to leverage recent funding from its acquisition by Roche to expand its product offerings and enhance its technology solutions. The company is focused on developing new products that improve cancer care and patient outcomes, although specific details on release dates have not been disclosed.

Additionally, Flatiron is considering expanding its market reach into international territories to leverage its expertise in oncology data solutions. The acquisition in February 2018, which is expected to be completed in the first half of that year, will provide substantial resources to support these growth initiatives.